Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alkermes plc
Industry Sector: HealthTechnology
CEO: Richard F. Pops
Number Of Employees: 1,800
Enterprise Value: $4,190,004,480
PE Ratio: 14.92
Exchange/Ticker 1: NASDAQ:ALKS
Exchange/Ticker 2: N/A
Latest Market Cap: $5,369,513,984
BioCentury | Mar 18, 2025
Management Tracks
Zenas names Lisa von Moltke head of R&D and CMO
Plus: CBC’s Lan Kang becomes CEO of Azkarra, and updates from Ionctura, Sunbird and Surf Bio
BioCentury | Nov 1, 2024
Management Tracks
Masashi Miyamoto to become chairman and CEO of Kyowa Kirin
Plus: Scott Koenig to step down as CEO of MacroGenics, and updates from Axonis and Myrobalan
BioCentury | Aug 19, 2024
Management Tracks
New commercial, regulatory heads at Fulcrum
Plus: Tiziana names Ivor Elrifi CEO, and updates from Soleno, Latigo, Fog and
BioCentury | Jul 19, 2024
Management Tracks
Remembering Lisa Burns, biotech’s ‘CEO whisperer’
An IR/PR pioneer, Burns connected CEOs, investors and analysts and played host to JPM’s best party
BioCentury | Jan 26, 2024
Product Development
Growing IL-18 field looks to enhance cell therapies via decoy evasion
As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
BioCentury | Nov 15, 2023
Deals
Alkermes oncology spinout Mural charts its future
Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics
BioCentury | Jul 26, 2023
Politics, Policy & Law
Rapid biomedical progress is not inevitable, Pops says
Alkermes CEO Richard Pops warns that price regulation, PBMs and FDA policies could slow transformation of science to medicine
BioCentury | Jul 25, 2023
Deals
Alnylam-Roche deal, plus insights on the IRA, FTC: a BioCentury podcast
How Alnylam deal fits biotech’s growth strategy. Plus: latest developments in IRA litigation and FTC M&A guidelines
BioCentury | Jun 29, 2023
Product Development
June 29 Quick Takes: Disclosure of impropriety jeopardizes integrity of BioXcel’s trial
Plus: Laekna completes $101M Hong Kong IPO, FDA again rebuffs Alvotech’s Humira biosimilar and updates from Vesalius, Alkermes and Vertex Ventures
BioCentury | Jun 21, 2023
Politics, Policy & Law
Fixing advisory committees could be Califf’s legacy
Successful revamp would improve the quality of FDA decisions, enhance public trust
Items per page:
1 - 10 of 364